Lars Gedda
Impact in
-
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Boron Compounds in Chemistry
- Oncology top 5%
- HER2/EGFR in Cancer Research
Papers in
-
- Radiopharmaceutical Chemistry and Applications 32
- Monoclonal and Polyclonal Antibodies Research 20
- Boron Compounds in Chemistry 17
-
- Lipid Membrane Structure and Behavior 10
- RNA Interference and Gene Delivery 7
- Co-authors
- Jörgen Carlsson (24 shared papers)Katarina Edwards (30 shared papers)Karl Andersson (9 shared papers)Vladimir Tolmachev (19 shared papers)Stefan Sjöberg (15 shared papers)Erika Bohl Kullberg (8 shared papers)Hanna Björkelund (6 shared papers)Anna Orlova (11 shared papers)
- Journals
- Cancer Biotherapy and Radiopharmaceuticals (7 papers)International Journal of Oncology (5 papers)Bioconjugate Chemistry (4 papers)PLoS ONE (4 papers)Tumor Biology (4 papers)
- Partner nations
- SwedenGermanyUnited States
In The Last Decade
Lars Gedda
89 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 107
- Radiology, Nuclear Medicine and Imaging 1.1k
- Oncology 409
- Biomaterials 195
- Molecular Biology 684
- Pharmaceutical Science 58
Countries citing papers authored by Lars Gedda
This map shows the geographic impact of Lars Gedda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Gedda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Gedda more than expected).
Fields of papers citing papers by Lars Gedda
This network shows the impact of papers produced by Lars Gedda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Gedda. The network helps show where Lars Gedda may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Gedda, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 92 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 134 | |
| 2 | 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. | 2006 | 94 |
| 3 | 2011 | 78 | |
| 4 | 2002 | 73 | |
| 5 | 2010 | 73 | |
| 6 | 2005 | 60 | |
| 7 | 2009 | 58 | |
| 8 | 1997 | 55 | |
| 9 | 1994 | 52 | |
| 10 | 2007 | 51 | |
| 11 | 2009 | 50 | |
| 12 | 2009 | 50 | |
| 13 | 2011 | 45 | |
| 14 | 2003 | 44 | |
| 15 | 2012 | 40 | |
| 16 | 2008 | 37 | |
| 17 | 2022 | 36 | |
| 18 | 2002 | 35 | |
| 19 | 2009 | 34 | |
| 20 | 1996 | 33 |
About Lars Gedda
Lars Gedda is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology, Oncology, Organic Chemistry and Biomaterials, having authored 92 papers that have together received 2.0k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (32 papers), Monoclonal and Polyclonal Antibodies Research (20 papers), HER2/EGFR in Cancer Research (19 papers), Boron Compounds in Chemistry (17 papers), Lipid Membrane Structure and Behavior (10 papers), Nanoparticle-Based Drug Delivery (9 papers), RNA Interference and Gene Delivery (7 papers) and Neuroblastoma Research and Treatments (7 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (1.1k citations), Oncology (409 citations), Biomaterials (195 citations), Molecular Biology (684 citations) and Pharmaceutical Science (58 citations). Lars Gedda has collaborated with scholars based in Sweden, Germany and United States. Frequent co-authors include Jörgen Carlsson, Katarina Edwards, Karl Andersson, Vladimir Tolmachev, Stefan Sjöberg, Erika Bohl Kullberg, Hanna Björkelund, Anna Orlova, Hans Lundqvist and Fredrik Y. Frejd. Their work appears in journals such as Cancer Biotherapy and Radiopharmaceuticals, International Journal of Oncology, Bioconjugate Chemistry, PLoS ONE and Tumor Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.